Case of Severe Cardiotoxicity in a Pediatric Patient After Fluorouracil Administration.
暂无分享,去创建一个
[1] R. Geller,et al. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. , 2017, The American journal of emergency medicine.
[2] M. Fakih,et al. Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity , 2016, Cancer.
[3] Jared M. Campbell,et al. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. , 2016, Pharmacogenomics.
[4] Kirsten Vistisen,et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. , 2013, Cancer treatment reviews.
[5] A. Frigo,et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer , 2009, British Journal of Cancer.
[6] M. Saif,et al. Fluoropyrimidine-associated cardiotoxicity: revisited , 2009 .
[7] V. Catalano,et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy , 2008, The Pharmacogenomics Journal.
[8] A. V. van Kuilenburg,et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. , 2002, Pharmacogenetics.
[9] A. Fandi,et al. Biology and treatment of nasopharyngeal cancer , 1995, Current opinion in oncology.
[10] D. Keefe,et al. Clinical Cardiotoxicity of 5‐Fluorouracil , 1993, Journal of clinical pharmacology.